Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/45039
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGarcía-Robles, M.J.
dc.contributor.authorSegura-Ortega, J.E.
dc.contributor.authorFafutis-Morris, M.
dc.date.accessioned2015-09-15T19:05:53Z-
dc.date.available2015-09-15T19:05:53Z-
dc.date.issued2013
dc.identifier.urihttp://hdl.handle.net/20.500.12104/45021-
dc.identifier.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-84923002932&partnerID=40&md5=71a6ee952c5e95e6cb6b19561ab160be
dc.identifier.urihttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=25447399
dc.description.abstractObesity is a world health problem that increases the risk for developing type 2 diabetes, cardiovascular disease, fatty liver, and some types of cancer. In postmenopausal women, it represents an important risk factor for the development of breast cancer (BC). Leptin is an adipokine that is secreted by fatty tissue, and high leptin levels are observed both in mouse models of obesity and in obese subjects. High levels of leptin promote the proliferation and progression of various types of cancer, including BC. This review provides a general overview of the biology of leptin, important laboratory studies, and animal and clinical models that have provided evidence for an active role of leptin in the proliferation, progression, and survival of mammary tumors. Finally, this review addresses the most recent studies on the use of leptin receptor antagonists as a novel therapeutic treatment for BC. " Copyright 2013, Mary Ann Liebert, Inc. 2013.",,,,,,"10.1089/jir.2012.0168",,,"http://hdl.handle.net/20.500.12104/45039","http://www.scopus.com/inward/record.url?eid=2-s2.0-84890087045&partnerID=40&md5=4e42411dab3840f78c5b7e7e0e648725
dc.description.abstracthttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23869900",,,,,,"12",,"Journal of Interferon and Cytokine Research",,"717
dc.description.abstract727",,"33",,"Scopus
dc.description.abstractWOS
dc.description.abstractMEDLINE",,,,"Index Medicus;Animals;Breast Neoplasms/ge [Genetics];Breast Neoplasms/me [Metabolism];Breast Neoplasms/th [Therapy];Disease Models, Animal;Energy Metabolism;Female;Homeostasis;Humans;Leptin/ge [Genetics];Leptin/me [Metabolism];Mice;Molecular Targeted Therapy;Receptors, Leptin/ai [Antagonists & Inhibitors];Receptors, Leptin/ch [Chemistry];Receptors, Leptin/ge [Genetics];Receptors, Leptin/me [Metabolism];Risk Factors;Signal Transduction",,,,,,,,"The biology of leptin and its implications in breast cancer: A general view",,"Review" "46849","123456789/35008",,,,"Moloeznik Gruer, Marcos Pablo",,"1998",,,,,,,,,,"0187-8611","http://hdl.handle.net/20.500.12104/45070",,,"Español",,,,"40",,"Ciudades",,"31-36",,"10",,"CLASE",,,,,,,,"Gobierno",,,,"Instrumento militar y transición a la democracia",,"journalArticle" "46800","123456789/35008",,"Sandoval-Talamantes, A.K., Centro de Investigación, Inmunología y Dermatología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, México, Av. Federalismo Norte 3102, Atemajac del ValleZapopan, Jalisco, Mexico; Brito-Luna, M.J., Instituto Dermatológico de Jalisco Dr. José Barba Rubio, Secretaria de Salud, Jalisco, México, Av. Federalismo Norte 3102, Atemajac del ValleZapopan, Jalisco, Mexico; Fafutis-Morris, M., Centro de Investigación, Inmunología y Dermatología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, México, Av. Federalismo Norte 3102, Atemajac del ValleZapopan, Jalisco, Mexico; Villanueva-Quintero, D.G., Instituto Dermatológico de Jalisco Dr. José Barba Rubio, Secretaria de Salud, Jalisco, México, Av. Federalismo Norte 3102, Atemajac del ValleZapopan, Jalisco, Mexico; Graciano-Machuca, O., Centro de Investigación, Inmunología y Dermatología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, México, Av. Federalismo Norte 3102, Atemajac del ValleZapopan, Jalisco, Mexico; Ramírez-Dueñas, M.G., Laboratorio de Inmunología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, México, Sierra mojada 950, Col. IndependenciaCP Guadalajara, Jalisco, Mexico; Alvarado-Navarro, A., Centro de Investigación, Inmunología y Dermatología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, México, Av. Federalismo Norte 3102, Atemajac del ValleZapopan, Jalisco, Mexico",,"Sandoval-Talamantes, A.K.
dc.description.abstractBrito-Luna, M.J.
dc.description.abstractFafutis-Morris, M.
dc.description.abstractVillanueva-Quintero, D.G.
dc.description.abstractGraciano-Machuca, O.
dc.description.abstractRamirez-Duenas, M.G.
dc.description.abstractAlvarado-Navarro, A.",,"2015",,"Psoriasis is characterized by the keratinocyte proliferation, which is induced by cytokines Th1 and Th17. Patients with plaque psoriasis present a chronic inflammatory response with high levels of interleukin (IL)-12 and IL-23. Various single-nucleotide polymorphisms (SNP) have been identified in the IL12B gene, such as SNP 3' UTR 1188 A/C (SNP rs3212227), which has been associated with susceptibility to developing plaque psoriasis and with the production of IL-12 and IL-23 in individuals of different ethnic groups. In this study, we determined whether there is an association of SNP rs3212227 with the susceptibility of developing plaque psoriasis and with serum levels of IL-12 and IL-23 in Mestizo population in western Mexico. We included 112 patients with psoriasis and 112 clinical healthy individuals in the study. The frequencies of genotypes A/A, A/C, and C/C in patients with plaque psoriasis were 41, 53, and 6%, respectively, while in the control group, these were 37, 53, and 10%, respectively, without finding statistically significant differences between both groups (p>. 0.05). Although IL-12 and IL-23 serum levels were higher in patients than in controls, we found no significant differences. The group of patients with genotype CC presented the highest levels of IL-23 (p<. 0.05). These data suggest that the SNP rs3212227 phenotype is not associated with the risk of developing plaque psoriasis or with IL-12 and IL-23 levels in Mestizo population in western Mexico. " 2014 European Federation of Immunological Societies.
dc.relation.isreferencedbyScopus
dc.relation.isreferencedbyMEDLINE
dc.titleThe 3'UTR 1188A/C polymorphism of IL-12p40 is not associated with susceptibility for developing plaque psoriasis in Mestizo population from western Mexico
dc.typeArticle
dc.identifier.doi10.1016/j.imlet.2014.10.004
dc.relation.ispartofjournalImmunology Letters
dc.relation.ispartofvolume163
dc.relation.ispartofissue2
dc.relation.ispartofpage221
dc.relation.ispartofpage226
dc.subject.keywordIL-12B; IL-23 polymorphism; Plaque psoriasis
dc.contributor.affiliationGarcía-Robles, M.J., Doctorado en Ciencias Biomedicas, CUCS, Universidad de Guadalajara, Guadalajara, Mexico; Segura-Ortega, J.E., Departamento de Gastroenterología, Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico; Fafutis-Morris, M., Doctorado en Ciencias Biomedicas, CUCS, Universidad de Guadalajara, Guadalajara, Mexico, Laboratorio de Inmunología, Departamento de Fisiología, CUCS, Universidad de Guadalajara, Sierra Mojada 950, Colonia Independencia Guadalajara Jalisco 44340, Mexico
dc.subject.headingIndex Medicus
Appears in Collections:Producción científica UdeG

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.